Literature DB >> 1355446

NMDA receptor activation stimulates phospholipase A2 and somatostatin release from rat cortical neurons in primary cultures.

L Tapia-Arancibia1, F Rage, M Récasens, J P Pin.   

Abstract

We have recently shown that glutamate exerts a stimulatory action on somatostatin secretion in cortical neurons essentially through NMDA receptor sites. Here, we investigated whether arachidonic acid release could be modified after NMDA receptor activation in cortical neurons in primary culture. We also studied whether pharmacological manipulation of phospholipase A2 could modify somatostatin release. We found that both glutamate and NMDA (N-methyl-D-aspartate) stimulated [3H]arachidonic acid release. NMDA-evoked arachidonic acid release was inhibited by MK-801 and TCP (two NMDA receptor-type antagonists), or by mepacrine, an inhibitor of phospholipase A2. NMDA-induced somatostatin release was inhibited by MK-801, mepacrine and by another phospholipase A2 inhibitor, p-bromophenacylbromide (pBPB). However, responses to NMDA were unaffected by H7, NDGA (nordihydroguaiaretic acid), indomethacin or by RHC 80267 (inhibitors of protein kinase C, lipooxygenase, cyclooxygenase and diacylglycerol lipase, respectively). Mepacrine (greater than or equal to 100 microM) decreased NMDA-stimulated phosphatidylinositol (PI) hydrolysis and at higher concentrations (250 microM) was also able to inhibit basal release whereas pBPB had no effect in the range of concentrations tested. Neomycin (which inhibits phosphatidylinositol metabolism by binding strongly and selectively to inositol phospholipids) reduced by 30% the NMDA-stimulated somatostatin release, although chronic treatment of neurons with the phorbol ester 12-myristate, 13-acetate (PMA) had no effect on this response. Melittin, an activator of phospholipase A2, was able to stimulate both arachidonic acid release and somatostatin secretion. High-performance liquid chromatography (HPLC) analysis of tritiated metabolites released from cortical neurons under basal or NMDA-stimulated conditions revealed that [3H]arachidonic acid was the only metabolite detectable. Furthermore, external addition of arachidonic acid increased somatostatin secretion. Our results show a correlation between the two parameters studied.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355446     DOI: 10.1016/0922-4106(92)90027-s

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Human immunodeficiency virus type 1 clade B and C gp120 differentially induce neurotoxin arachidonic acid in human astrocytes: implications for neuroAIDS.

Authors:  Thangavel Samikkannu; Marisela Agudelo; Nimisha Gandhi; Pichili V B Reddy; Zainulabedin M Saiyed; Donald Nwankwo; Madhavan P N Nair
Journal:  J Neurovirol       Date:  2011-04-14       Impact factor: 2.643

2.  Potentiation of a metabotropic glutamatergic response following NMDA receptor activation in rat hippocampus.

Authors:  A Lüthi; B H Gähwiler; U Gerber
Journal:  Pflugers Arch       Date:  1994-05       Impact factor: 3.657

3.  Cytosolic phospholipase A2 alpha inhibition prevents neuronal NMDA receptor-stimulated arachidonic acid mobilization and prostaglandin production but not subsequent cell death.

Authors:  Ava L Taylor; Joseph V Bonventre; Tracy F Uliasz; James A Hewett; Sandra J Hewett
Journal:  J Neurochem       Date:  2008-06-28       Impact factor: 5.372

4.  Apoptosis and the receptor specificity of its mechanisms during the neurotoxic action of glutamate.

Authors:  A A Evstratova; E V Mironova; E A Dvoretskova; S M Antonov
Journal:  Neurosci Behav Physiol       Date:  2009-04-02

5.  Chronic administration of valproic acid reduces brain NMDA signaling via arachidonic acid in unanesthetized rats.

Authors:  Mireille Basselin; Lisa Chang; Mei Chen; Jane M Bell; Stanley I Rapoport
Journal:  Neurochem Res       Date:  2008-05-07       Impact factor: 3.996

6.  Chronic carbamazepine administration reduces N-methyl-D-aspartate receptor-initiated signaling via arachidonic acid in rat brain.

Authors:  Mireille Basselin; Nelly E Villacreses; Mei Chen; Jane M Bell; Stanley I Rapoport
Journal:  Biol Psychiatry       Date:  2007-07-12       Impact factor: 13.382

7.  Spinal mediators of hyperalgesia.

Authors:  S T Meller; G F Gebhart
Journal:  Drugs       Date:  1994       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.